Since ICIs can alter immune responses, this study could provide valuable insights into how IgA and other immune markers in peripheral blood might influence treatment responses, potentially serving as biomarkers for prognosis or treatment efficacy in cervical cancer patients. This evidence concerns the gene CD79A and cervical carcinoma.